N/A
N=10
A Study to Confirm the Safety of High Frequency DRG Stimulator in Patients With Chronic Lower Limb Pain
Failed Back Surgery Syndrome · Complex Regional Pain Syndrome (CRPS)
Bottom Line
View on ClinicalTrials.gov: NCT03285113 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jan 2021
Primary outcome: Primary: Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE) — 5 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- GiMer Medical MN 1000 External Stimulator (Device)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- GiMer Medical
- Primary completion
- Feb 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE) |
5 | — |
| SECONDARY Change in Pain Measured by Visual Analog Scale (VAS) |
-2.7 | — |
| SECONDARY Incidence of Paresthesia |
— | — |
| SECONDARY Change in Pain Medication Consumption |
3 | — |
Summary
This study is a prospective, single-arm, open label, single center pilot study to confirm the safety of a ultrahigh frequency DRG stimulator in patients with chronic lower limb pain. The actual trial length is 5 days. Pts will be given ultrahigh frequency pulse stimulation, and VAS will be obtained after 3-4 hours of each stimulation.
Eligibility Criteria
Inclusion Criteria
- Age ≧20 and ≦75
- Have a symptom of complex regional pain syndrome (CRPS), failed back surgery syndrome (FBSS), lower limb pain with or without lower back pain with a diagnosis related to spinal lesion and pain history of >6 months.
- Have an average pain score >5 by Visual Analogue Scale (VAS) on inclusion.
- Has failed to achieve adequate pain relief from prior pharmacologic treatments.
- In the judgement of the investigator, the subject is an appropriate candidate for the trial procedure
- The subject is willing and able to comply with the procedure and requirements of this trial.
- The participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with IRB requirements.
Exclusion Criteria
- Have evidence of a mental or psychological condition that affects pain perception and has difficulty/disability performing objective pain assessment, or have previously failed mental or psychological assessments administered by a psychiatrist that may be deemed to indicate the subject's lack of suitability for participation in this study.
- Subject has exhibited escalating or changing pain condition within the past 30 days as evidenced by Investigator examination.
- Be on anticoagulant medication with INR >1.5 or platelet count less than 100,000/μL, peripheral vascular diseases (PVDs), visceral pain or uncontrolled Diabetes mellitus (DM).
- Has had corticosteroid therapy at an intended site of stimulation within the past 30 days.
- Pain medication(s) dosages(s) are not stable for at least 30 days.
- Has previously failed spinal cord stimulation therapy.
- Currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump or subject requires magnetic resonance imaging (MRIs) or diathermy.
- Has pain only within a cervical or thoracic distribution.
- Have a current diagnosis of cancer with active symptoms
- Have a known terminal illness with life expectancy less than one year
- Have a systematic or local infection
- Currently has an indwelling device that may pose an increased risk of infection.
- Be pregnant or breast feeding
- Have a medical history of drug or alcohol addiction within the past 2 years.
- Participation in any investigational study in the last 30 days or current enrollment in any trial.
- Be currently involved in an injury claim law suit or medically related litigation, including workers compensation.
- Be a prisoner.
Data sourced from ClinicalTrials.gov (NCT03285113). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.